4,414 results found

In Chudik v. Hirschfeld, No. 2020-1833 (Fed. Cir. Feb. 8, 2021), the Federal Circuit held that C-delay patent term adjustment is not available if the applicant elects to continue examination

In Chudik v. Hirschfeld, No. 2020-1833 (Fed. Cir. Feb. 8, 2021), the Federal Circuit held that C-delay patent term extension is not available if the applicant elects to continue examination...

This practice note teaches patent prosecutors how to rebut a patent examiner's prima facie case of obviousness. For a discussion of how to attack the examiner's prima facie case, thus possibly eliminating the need for rebuttal...

In BlephEx, LLC v. Myco Industries, Inc., Nos. 21-1149, 21-1365 (Fed. Cir. Feb. 3, 2022), the Federal Circuit affirmed the Eastern District of Michigan's preliminary injunction enjoining Myco from selling its product AB Max, ...

A North Dakota court recently prohibited the parties from referring to the patent owner during trial by using derogatory, disparaging, or pejorative references, such as "patent troll" or "pirate."

In Ironburg Inventions Ltd., v. Valve Corp., No. 2021-2296 (Fed. Cir. April 3, 2023), the Federal Circuit affirmed the district court's finding of willful infringement, claim construction...

"Patent trolls," also known as patent assertion entities ("PAEs") or non-practicing entities ("NPEs"), are known for filing patent infringement lawsuits targeting general-purpose internet services...

In Chandler v. Phoenix Services LLC, No. 2020-1848 (Fed. Cir. June 10, 2021), the Federal Circuit transferred the case to the United States Court of Appeals for the Fifth Circuit finding that it lacked jurisdiction.

In Packet Intelligence LLC v. NetScout Sys., Inc., No. 2019-2041 (Fed. Cir. July 14, 2020), the Federal Circuit affirmed the district court's holdings on infringement...

Artificial intelligence, or AI, is rapidly transforming the world of medicine.

Thus, there would be no defense of divided infringement because through this attribution, physicians would directly infringe the patent claims, and the generic drug manufacturer defendants would induce such infringement because their drug labeling instructs physicians to follow the patented regimen.

In Uniloc USA, Inc. v. Apple Inc., No. 21-1568 (Fed. Cir. Feb. 9, 2022), the Federal Circuit vacated and remanded the district court's denial of Uniloc's request to seal third-party licensing information...

In Cooperative Entertainment, Inc. v. Kollective Technology, Inc., No. 2021-2167 (Fed. Cir. Sept. 28, 2022), the Federal Circuit reversed a Northern District of California decision granting...

In Cellspin Soft, Inc. v. Fitbit, Inc., No. 2018-1817 et al. (Fed. Cir. June. 25, 2019), the Federal Circuit vacated and remanded the district court's dismissal

Welcome to the Last Month at the Federal Circuit – a look at recent Federal Circuit decisions impacting the intellectual property community.

Welcome to the Last Month at the Federal Circuit—a look at recent Federal Circuit decisions impacting the intellectual property community.

Welcome to the Last Month at the Federal Circuit—a look at recent Federal Circuit decisions impacting the intellectual property community. In this episode...

In this podcast, Finnegan partner Kathleen Daley offers insight into three recently-decided Federal Circuit cases and their potential implications: